These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37747942)

  • 1. Low-Value Prostate Cancer Screening Among Young Men With Private Insurance.
    Lange SM; Vehawn J; Choudry MM; Ambrose JP; Cluff CM; Haaland BA; Paudel N; Chipman J; Hanson HA; O'Neil BB
    Urol Pract; 2024 Jan; 11(1):110-115. PubMed ID: 37747942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
    Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
    BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downstream tests, treatments, and annual direct payments in older men cared for by primary care providers with high or low prostate-specific antigen screening rates using 100 percent Texas U.S. Medicare public insurance claims data: a retrospective cohort study.
    Zanwar P; Lin YL; Kuo YF; Goodwin JS
    BMC Health Serv Res; 2016 Jan; 16():17. PubMed ID: 26772175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disparities Associated with Shared Decision-making in Prostate Cancer Screening.
    Basin MF; Crane K; Basnet A; Chandrasekar T; Shapiro O; Jacob JM; Bratslavsky G; Goldberg H
    Eur Urol Focus; 2023 Nov; 9(6):1008-1015. PubMed ID: 37198068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study.
    Young GJ; Harrison S; Turner EL; Walsh EI; Oliver SE; Ben-Shlomo Y; Evans S; Lane JA; Neal DE; Hamdy FC; Donovan JL; Martin RM; Metcalfe C
    BMJ Open; 2017 Oct; 7(10):e017729. PubMed ID: 29084797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen testing rates in high-risk populations: results from the All of Us Research Program.
    Morley F; Iyer HS; Tamimi RM; Nanus DM; Rebbeck TR; Kensler KH
    Cancer Causes Control; 2024 Mar; 35(3):509-521. PubMed ID: 37878135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen testing among the elderly in community-based family medicine practices.
    Hudson SV; Ohman-Strickland P; Ferrante JM; Lu-Yao G; Orzano AJ; Crabtree BF
    J Am Board Fam Med; 2009; 22(3):257-65. PubMed ID: 19429731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining low-value PSA testing in a large retrospective cohort: Finding common ground between discordant guidelines.
    O'Neil B; Martin C; Kapron A; Flynn M; Kawamoto K; Cooney KA
    Cancer Epidemiol; 2018 Oct; 56():112-117. PubMed ID: 30130683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of receipt of prostate cancer screening among men living with HIV enrolled in an urban HIV Clinic in the United States over the period of 2000-2020.
    Pirsl F; Keruly JC; Moore RD; Lau B; Joshu CE
    Prev Med; 2024 Jul; 184():108000. PubMed ID: 38735585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporal and Racial Trends in Prostate-specific Antigen Screening for U.S. Men With a Family History of Prostate Cancer.
    Dalela D; Malchow T; Butaney M; Majdalany S; Corsi NJ; Rakic I; Sood A; Rogers C; Abdollah F
    Urol Pract; 2023 Sep; 10(5):484-492. PubMed ID: 37347799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unravelling the prostate-specific antigen controversy: a West of Scotland perspective.
    Zafar N; Miller S; Leburn V; Qureshi KN; Rajan P
    Scott Med J; 2014 May; 59(2):126-9. PubMed ID: 24682103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-screening Discussions and Prostate-Specific Antigen Testing for Prostate Cancer Screening.
    Li J; Zhao G; Hall IJ
    Am J Prev Med; 2015 Aug; 49(2):259-63. PubMed ID: 25997905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinician Factors Associated With Prostate-Specific Antigen Screening in Older Veterans With Limited Life Expectancy.
    Tang VL; Shi Y; Fung K; Tan J; Espaldon R; Sudore R; Wong ML; Walter LC
    JAMA Intern Med; 2016 May; 176(5):654-61. PubMed ID: 27042937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shared decision making and prostate-specific antigen based prostate cancer screening following the 2018 update of USPSTF screening guideline.
    Jiang C; Fedewa SA; Wen Y; Jemal A; Han X
    Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):77-80. PubMed ID: 32296126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of ≥3.0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial.
    Frånlund M; Carlsson S; Stranne J; Aus G; Hugosson J
    BJU Int; 2012 Sep; 110(5):638-43. PubMed ID: 22540895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decision fatigue in low-value prostate cancer screening.
    Hunt TC; Ambrose JP; Haaland B; Kawamoto K; Dechet CB; Lowrance WT; Hanson HA; O'Neil BB
    Cancer; 2021 Sep; 127(18):3343-3353. PubMed ID: 34043813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discrepancies between guidelines and clinical practice regarding prostate-specific antigen testing.
    Hamoen EH; Reukers DF; Numans ME; Barentsz JO; Witjes JA; Rovers MM
    Fam Pract; 2013 Dec; 30(6):648-54. PubMed ID: 24107269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
    Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
    Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the prostate-specific antigen test in the U.S. for men age 30 to 64 in 2011 to 2017 using a large commercial claims database: Implications for practice interventions.
    Shahangian S; Sharma KP; Fan L; Siegel DA
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1365. PubMed ID: 33934557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial.
    Carlsson SV; Arnsrud Godtman R; Pihl CG; Vickers A; Lilja H; Hugosson J; Månsson M
    Eur Urol; 2023 Feb; 83(2):103-109. PubMed ID: 36334968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.